866-997-4948(US-Canada Toll Free)

Refractory Multiple Myeloma - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Feb 2014

Category :

Diseases & Conditions

No. of Pages : 300 Pages

Global Markets Direct’s, ‘Refractory Multiple Myeloma - Pipeline Review, H1 2014’, provides an overview of the Refractory Multiple Myeloma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Refractory Multiple Myeloma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Refractory Multiple Myeloma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Refractory Multiple Myeloma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Introduction
Global Markets Direct Report Coverage
Refractory Multiple Myeloma Overview
Therapeutics Development
Pipeline Products for Refractory Multiple Myeloma - Overview
Pipeline Products for Refractory Multiple Myeloma - Comparative Analysis
Refractory Multiple Myeloma - Therapeutics under Development by Companies
Refractory Multiple Myeloma - Therapeutics under Investigation by Universities/Institutes
Refractory Multiple Myeloma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Refractory Multiple Myeloma - Products under Development by Companies
Refractory Multiple Myeloma - Products under Investigation by Universities/Institutes
Refractory Multiple Myeloma - Companies Involved in Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
Kyowa Hakko Kirin Co., Ltd.
Sanofi
Eli Lilly and Company
GlaxoSmithKline plc
Genentech, Inc.
Piramal Enterprises Limited
Prolexys Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
Novartis AG
Astellas Pharma Inc.
Pfizer Inc.
Exelixis, Inc.
Celgene Corporation
Onyx Pharmaceuticals, Inc.
Incyte Corporation
Oncolytics Biotech Inc.
Pharmacyclics, Inc.
Array BioPharma Inc.
MorphoSys AG
Senesco Technologies, Inc.
Threshold Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Acceleron Pharma, Inc.
Altor BioScience Corporation
Stemline Therapeutics, Inc.
Acetylon Pharmaceuticals, Inc.
Pharma Mar, S.A.
Janssen Biotech, Inc.
AbbVie Inc.
Oncopeptides AB
Senhwa Biosciences
Refractory Multiple Myeloma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ixazomib citrate - Drug Profile
panobinostat - Drug Profile
carfilzomib - Drug Profile
elotuzumab - Drug Profile
plitidepsin - Drug Profile
bendamustine - Drug Profile
ibrutinib - Drug Profile
ruxolitinib phosphate - Drug Profile
ARRY-520 - Drug Profile
ALT-801 - Drug Profile
pomalidomide - Drug Profile
chloroquine + [bortezomib] + [cyclophosphamide] - Drug Profile
Melflufen - Drug Profile
Circularly Permuted TRAIL - Drug Profile
alisertib - Drug Profile
daratumumab - Drug Profile
PRLX-93936 - Drug Profile
carfilzomib - Drug Profile
cabozantinib (s)-malate - Drug Profile
SNS-01T - Drug Profile
SL-401 - Drug Profile
TH-302 - Drug Profile
P-276 - Drug Profile
MOR-202 - Drug Profile
KW-2478 - Drug Profile
palbociclib - Drug Profile
luminespib - Drug Profile
plerixafor - Drug Profile
ricolinostat - Drug Profile
LY-2812176 - Drug Profile
tabalumab - Drug Profile
BMS-833923 - Drug Profile
dalantercept - Drug Profile
SAR-650984 - Drug Profile
dasatinib - Drug Profile
ganetespib - Drug Profile
pelareorep - Drug Profile
ulocuplumab - Drug Profile
tipifarnib - Drug Profile
veliparib - Drug Profile
silmitasertib - Drug Profile
pomalidomide - Drug Profile
afuresertib - Drug Profile
MV-NIS Vaccine - Drug Profile
ABT-199 - Drug Profile
RG-7598 - Drug Profile
LGH-447 - Drug Profile
hydroxychloroquine + sirolimus - Drug Profile
Refractory Multiple Myeloma - Recent Pipeline Updates
Refractory Multiple Myeloma - Dormant Projects
Refractory Multiple Myeloma - Discontinued Products
Refractory Multiple Myeloma - Product Development Milestones
Featured News & Press Releases

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Table


Number of Products under Development for Refractory Multiple Myeloma, H1 2014
Number of Products under Development for Refractory Multiple Myeloma - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Development by Companies, H1 2014 (Contd..1)
Number of Products under Development by Companies, H1 2014 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Products under Development by Companies, H1 2014
Products under Development by Companies, H1 2014 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2014
Refractory Multiple Myeloma - Pipeline by Bristol-Myers Squibb Company, H1 2014
Refractory Multiple Myeloma - Pipeline by Johnson & Johnson, H1 2014
Refractory Multiple Myeloma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2014
Refractory Multiple Myeloma - Pipeline by Sanofi, H1 2014
Refractory Multiple Myeloma - Pipeline by Eli Lilly and Company, H1 2014
Refractory Multiple Myeloma - Pipeline by GlaxoSmithKline plc, H1 2014
Refractory Multiple Myeloma - Pipeline by Genentech, Inc., H1 2014
Refractory Multiple Myeloma - Pipeline by Piramal Enterprises Limited , H1 2014
Refractory Multiple Myeloma - Pipeline by Prolexys Pharmaceuticals, Inc., H1 2014
Refractory Multiple Myeloma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014
Refractory Multiple Myeloma - Pipeline by Novartis AG, H1 2014
Refractory Multiple Myeloma - Pipeline by Astellas Pharma Inc., H1 2014
Refractory Multiple Myeloma - Pipeline by Pfizer Inc., H1 2014
Refractory Multiple Myeloma - Pipeline by Exelixis, Inc., H1 2014
Refractory Multiple Myeloma - Pipeline by Celgene Corporation, H1 2014
Refractory Multiple Myeloma - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014
Refractory Multiple Myeloma - Pipeline by Incyte Corporation, H1 2014
Refractory Multiple Myeloma - Pipeline by Oncolytics Biotech Inc., H1 2014
Refractory Multiple Myeloma - Pipeline by Pharmacyclics, Inc., H1 2014
Refractory Multiple Myeloma - Pipeline by Array BioPharma Inc., H1 2014
Refractory Multiple Myeloma - Pipeline by MorphoSys AG, H1 2014
Refractory Multiple Myeloma - Pipeline by Senesco Technologies, Inc., H1 2014
Refractory Multiple Myeloma - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014
Refractory Multiple Myeloma - Pipeline by Synta Pharmaceuticals Corp., H1 2014
Refractory Multiple Myeloma - Pipeline by Acceleron Pharma, Inc., H1 2014
Refractory Multiple Myeloma - Pipeline by Altor BioScience Corporation, H1 2014
Refractory Multiple Myeloma - Pipeline by Stemline Therapeutics, Inc., H1 2014
Refractory Multiple Myeloma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2014
Refractory Multiple Myeloma - Pipeline by Pharma Mar, S.A., H1 2014
Refractory Multiple Myeloma - Pipeline by Janssen Biotech, Inc., H1 2014
Refractory Multiple Myeloma - Pipeline by AbbVie Inc., H1 2014
Refractory Multiple Myeloma - Pipeline by Oncopeptides AB, H1 2014
Refractory Multiple Myeloma - Pipeline by Senhwa Biosciences, H1 2014
Assessment by Monotherapy Products, H1 2014
Assessment by Combination Products, H1 2014
Number of Products by Stage and Target, H1 2014
Number of Products by Stage and Mechanism of Action, H1 2014
Number of Products by Stage and Route of Administration, H1 2014
Number of Products by Stage and Molecule Type, H1 2014
Refractory Multiple Myeloma Therapeutics - Recent Pipeline Updates, H1 2014
Refractory Multiple Myeloma - Dormant Projects, H1 2014
Refractory Multiple Myeloma - Discontinued Products, H1 2014

List of Chart


Number of Products under Development for Refractory Multiple Myeloma, H1 2014
Number of Products under Development for Refractory Multiple Myeloma - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Assessment by Monotherapy Products, H1 2014
Assessment by Combination Products, H1 2014
Number of Products by Top 10 Target, H1 2014
Number of Products by Stage and Top 10 Target, H1 2014
Number of Products by Top 10 Mechanism of Action, H1 2014
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
Number of Products by Top 10 Route of Administration, H1 2014
Number of Products by Stage and Top 10 Route of Administration, H1 2014
Number of Products by Top 10 Molecule Type, H1 2014
Number of Products by Stage and Top 10 Molecule Type, H1 2014

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *